1-2 of 2
Frank Diehl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B26: Actionable mutations in cell-free DNA in plasma of patients with advanced cancers referred for experimental targeted therapies.

Filip Janku, Philipp Angenendt, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Veronica R. Holley, Siqing Fu, David S. Hong, Jennifer J. Wheler, Sarina A. Piha-Paul, Ralph G. Zinner, Daniel D. Karp, Vivek Subbiah, Kevin B. Kim, Funda Meric-Bernstam, Frank Diehl, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B26.
DOI: https://doi.org/10.1158/1535-7163.TARG-13-B26
Published: 01 November 2013
View article
Journal Articles

Abstract B35: Acquired KRAS mutations after anti-EGFR therapy partially derive from low-frequency clones detectable in the primary tumor.

Maria Pia Morelli, Michael Overman, Arvind Dasari, Ali Kazmi, Edoardo Vilar-Sanchez, Cathy Eng, Bryan Kee, Laurel Deaton, Chris Garrett, Frank Diehl, Dipen Maru, Philipp Angenendt, Scott Kopetz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B35.
DOI: https://doi.org/10.1158/1535-7163.TARG-13-B35
Published: 01 November 2013
View article